- Home
- LPRO vs CADL Comparison
LPRO vs CADL Comparison
Compare LPRO & CADL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPRO
- CADL
- Stock Information
- Founded
- LPRO 2000
- CADL 1999
- Country
- LPRO United States
- CADL United States
- Employees
- LPRO N/A
- CADL N/A
- Industry
- LPRO Finance: Consumer Services
- CADL Biotechnology: Pharmaceutical Preparations
- Sector
- LPRO Finance
- CADL Health Care
- Exchange
- LPRO Nasdaq
- CADL Nasdaq
- Market Cap
- LPRO 232.4M
- CADL 250.0M
- IPO Year
- LPRO N/A
- CADL 2021
- Fundamental
- Price
- LPRO $2.50
- CADL $6.43
- Analyst Decision
- LPRO Buy
- CADL Strong Buy
- Analyst Count
- LPRO 6
- CADL 5
- Target Price
- LPRO $3.44
- CADL $21.40
- AVG Volume (30 Days)
- LPRO 1.2M
- CADL 1.0M
- Earning Date
- LPRO 08-07-2025
- CADL 08-12-2025
- Dividend Yield
- LPRO N/A
- CADL N/A
- EPS Growth
- LPRO N/A
- CADL N/A
- EPS
- LPRO N/A
- CADL N/A
- Revenue
- LPRO $17,672,000.00
- CADL N/A
- Revenue This Year
- LPRO $314.67
- CADL N/A
- Revenue Next Year
- LPRO $15.32
- CADL N/A
- P/E Ratio
- LPRO N/A
- CADL N/A
- Revenue Growth
- LPRO N/A
- CADL N/A
- 52 Week Low
- LPRO $0.70
- CADL $3.79
- 52 Week High
- LPRO $6.92
- CADL $14.60
- Technical
- Relative Strength Index (RSI)
- LPRO 66.93
- CADL 66.44
- Support Level
- LPRO $2.36
- CADL $5.78
- Resistance Level
- LPRO $2.56
- CADL $6.42
- Average True Range (ATR)
- LPRO 0.15
- CADL 0.37
- MACD
- LPRO 0.04
- CADL 0.17
- Stochastic Oscillator
- LPRO 91.97
- CADL 98.89
About LPRO Open Lending Corporation
Open Lending Corp is engaged in providing automated lending services to financial institutions. The company offers loan analytics, risk-based pricing, risk modeling, and automated decision technology. Its Lenders Protection Program ("LPP") enables automotive lenders to make loans that are largely insured against, losses from defaults.
About CADL Candel Therapeutics Inc.
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.